Capricor Therapeutics' Securities Class Action Lawsuit Update

Author: Olivia Taylor Updated: 09-11-2025 08:57 AM

Understanding Capricor Therapeutics' Class Action Lawsuit

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a company known for its innovative approaches in the biotech field, is currently facing a class action lawsuit related to potential securities fraud. Shareholders who purchased shares during the specified class period are encouraged to stay informed and consider their options.

Important Dates for Shareholders

This class action covers the shares purchased between October 9, 2024, and July 10, 2025. Shareholders should be vigilant about important deadlines, notably the approaching cutoff on September 15, 2025. This date marks the last day to register your interest.

The Allegations Against Capricor

At the heart of this lawsuit are allegations that Capricor misled investors about its lead therapy candidate, deramiocel. Investors were led to believe that Capricor was on track to secure a Biologics License Application (BLA) approval from the FDA. This confidence was shaken when news broke that the application had encountered significant hurdles, leading to a sharp decline in the stock price.

Specifically, on July 11, 2025, Capricor revealed it received a Complete Response Letter (CRL) from the FDA, which stated that the application did not meet the required standards for proof of effectiveness, needing more clinical data. This news baffled many investors who had trusted the positive projections provided previously.

Impact on Stock Prices

The fallout from the FDA’s letter was immediate and severe. The stock plummeted from $11.40 to $7.64 per share within a day, reflecting a significant loss for investors who bought shares during the class period. It highlights the risks associated with investing in biotechnology firms, especially those still navigating the regulatory landscape.

Next Steps for Investors

If you are a shareholder who falls within the specified dates, taking action is vital. Registration for participation in the lawsuit provides you with updates on case status and your rights as a shareholder. It’s important to ensure your voice is heard and protect your investment.

Why Choose the Gross Law Firm?

The Gross Law Firm is a highly esteemed group recognized for its commitment to transparency and the rights of investors. They focus on cases where deceit and unlawful practices have occurred in the corporate sector. The firm seeks to hold companies accountable and aims for recovery on behalf of investors affected by misleading practices.

Contacting the Firm

For those who wish to learn more or register, The Gross Law Firm is available to assist. They can provide insights into the class action process and answer any questions you may have about your individual situation. It's also important to remember that there is no cost to register or participate in this case.

Frequently Asked Questions

What is the deadline to register for the class action?

The deadline to register for the class action lawsuit against Capricor Therapeutics is September 15, 2025.

How can I know if I qualify to participate?

If you purchased shares of Capricor between October 9, 2024, and July 10, 2025, you may qualify to participate in the class action lawsuit.

What are the potential outcomes of the lawsuit?

The lawsuit aims to seek compensation for shareholders who suffered losses due to allegedly misleading information provided by the company.

Why is the lawsuit significant for investors?

This class action could set a precedent for how investors are treated in securities fraud cases, particularly within the biotech industry.

How can I get updates on the case?

By registering for the class action, you will receive status updates and relevant information throughout the lifespan of the case.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.